Date: 2017-08-08
Type of
information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of development program
Company: RXi Pharmaceuticals (USA - MA)
Product: RXI-762 and RXI-804
Action
mechanism: immune checkpoint inhibitor/self-delivering RNAi (sd-rxRNA®). Self-delivering’ RNAi compounds or sd-rxRNA provide an alternative approach to RNA delivery problems. These products are hybrid oligonucleotide compounds ; the proprietary combination of chemical modifications that results in spontaneous cellular uptake of sd-rxRNA without the need for a delivery vehicle. sd-rxRNA has a single-stranded phosphorothioate region, a short duplex region, and contains a variety of nuclease-stabilizing and lipophilic chemical modifications. The combination of these features allows sd-rxRNA to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity.
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On August 8, 2017, RXi Pharmaceuticals announced that it has selected two self-delivering RNAi (sd-rxRNA®) compounds from its immuno-oncology pipeline for preclinical development. For oncology treatments based on adoptive cell transfer (ACT), compounds RXI-762 and RXI-804 suppress the expression of immune checkpoint proteins PD-1 and TIGIT respectively, which can result in an improved efficacy to the targeted tumors. This decision triggered the selection of a manufacturing facility to initiate production of cGMP grade material, initially for the first of these two compounds (RXI-762). The latter also supports moving RXI-762 into clinical development as early as 2018 as part of an ACT therapy.
- RXi's immuno-oncology program with sd-rxRNA provides a versatile approach to improve upon well-established ACT methodologies. The company has identified lead compounds for a number of immune checkpoint targets that provide a long-lasting effect, individually and in combination, with target gene silencing demonstrated in various immune effector cells relevant in cancer immunotherapy, including CAR-T cells, TILs, and NK cells.
Is
general: Yes
